Screener
Kymera Therapeutics KYMR Other Nonoperating Expense
Other Nonoperating Expense at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingExpense.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Loss from operations | (75,607) | (84,557) | (159,763) | (158,983) |
| Other income (expense): | ||||
| Interest and other income | 14,477 | 8,051 | 29,459 | 16,968 |
| Interest and other expense | (81) | (108) | (141) | (180) |
| Total other income: | 14,396 | 7,943 | 29,318 | 16,788 |
| Net loss | $(61,211) | $(76,614) | $(130,445) | $(142,195) |
| Other comprehensive loss: | ||||
| Unrealized (loss) gain on marketable securities | (2,963) | 337 | (8,957) | 1,764 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's other nonoperating expense?
- Kymera Therapeutics (KYMR) reported other nonoperating expense of $81K in Q2 2026.
- How has Kymera Therapeutics's other nonoperating expense changed year-over-year?
- Kymera Therapeutics's other nonoperating expense decreased by 25.0% year-over-year, from $108K to $81K.
- What is the long-term trend for Kymera Therapeutics's other nonoperating expense?
- Over 4 years (2021 to 2025), Kymera Therapeutics's other nonoperating expense has grown at a 20.8% compound annual growth rate (CAGR), from $173K to $368K.
- What does other nonoperating expense mean?
- Other Nonoperating Expense as reported by Kymera Therapeutics, Inc. Common Stock.
Ask your AI about Kymera Therapeutics's other nonoperating expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude